Re-evaluation of the phenotype caused by the common MATR3 p.Ser85Cys mutation in a new family

INTRODUCTION
Late-onset autosomal dominant vocal cord and pharyngeal distal myopathy (VCPDM) was first described in an American family. A p.Ser85Cys mutation in MATR3 gene was later identified in this family, and also in one Bulgarian family and very recently, in seven families—six German and one Asian. Muscle pathology of VCPDM was dominated by rimmed-vacuolar fibre degeneration. This year, two other mutations in MATR3, p.Phe115Cys and pThr622Ala, have been reported to cause autosomal dominant amyotrophic lateral sclerosis (ALS). The original American p.Ser85Cys mutated family was re-evaluated and the authors stated: “These clinical findings supported reclassification of this condition as slowly progressive ALS, and the presence of upper motor neuron signs in the form of brisk reflexes ruled out myopathy as the only cause of disease in this family.”

We report a new family with the p.Ser85Cys mutation in MATR3, in which muscle atrophy and weakness are caused by progressive degenerative myopathy without any evidence of lower motor neuron defects.

METHODS
We investigated an American family with four affected siblings. Patients II.1, II.2 and II.4 were more extensively examined and followed for 7, 9 and 8 years, respectively. The father and one of his brothers were affected (figure 1A). Muscle MRI was performed in the proband (II.2) and in the younger brother (II.4). Muscle biopsies were obtained from three patients and examined by standard histochemical and immunohistochemical stainings with antibodies for Matrin 3, TDP-43, p62, SMI-31 and myosin A4.74, slow (MHCs), neonatal (MHCn) and developmental (MHCd) isoforms. Immunofluorescence analysis was performed with conventional methods using antibodies for G3BP and TIA1 C-terminus. Matrin 3 distribution was analysed from soluble cytoplasmic and nuclear fractions using western blotting.
Blood samples of all siblings in generation II were obtained and DNA was extracted by standard methods. Whole exome sequencing was performed on patient II.2 at ATLAS Biolabs GmbH using SeqCap EZ Human Exome Library V2.0 (Roche NimbleGen), and captured DNA was sequenced on Illumina HiSeq 2000 platform, 2x100 bp. Reads were processed following the Genome Analysis Toolkit best practices pipeline and the Human Gene Mutation Database was used to detect previously reported pathogenic mutations. Sanger sequencing was performed to confirm the findings.

RESULTS

The age of onset ranged from 31 to 48 years, and the first manifestation was either weakness in the hands or legs causing difficulty in dexterity, or standing on heels and toes. The weakness slowly progressed to proximal upper and lower limb muscles. Wasting of the small hand muscles was evident followed by atrophy in the distal lower leg and forearm (figure 1B). Waddling and steppage gait was observed. Fasciculations were absent in all siblings. In two patients, brisk reflexes without clonus or spread were noted; there were no definite pathological pyramidal tract reflexes (Hoffman, crossed adductors, Babinski sign). Several years after disease onset, two patients had mild to moderate hypophonia and dysphagia. Two patients did not have respiratory symptoms; the other two had dyspnoea on exertion, reduced forced vital capacity (50%), or both.

Creatine kinase (CK) levels were normal or marginally elevated. Electromyography studies of all patients were consistent with myopathic changes. Fasciculations were absent. No chronic neurogenic changes (eg, large amplitude or long duration motor unit potentials) were observed in any of the studies. MRI showed marked fatty degeneration of dystrophic type in soleus and medial gastrocnemius in both patients studied (figure 1C). Less severe changes were observed in the anterolateral lower leg compartment and hamstrings in IL4. In muscle biopsy taken from the left tibialis anterior (II.2), there were numerous rimmed-vacuolated fibres (figure 1D). MyHC double staining showed a normal fibre type distribution without grouping. MHCd labelled most of the highly atrophic fibres and these were reactive for MHCn, although with less intensity in the moderately atrophic fibres and not in MHCd negative fibres. Matrin 3 immunohistochemistry showed a loss of protein in the central parts of myonuclei (figure 1D). Myofibrillar myopathy markers myotilin, desmin, αB-crystallin, and ectopic cytoplasmic dystrophin were negative, whereas TDP-43, p62, and SMI-31 accumulated in rimmed-vacuolar fibres (data not shown).

Electron microscopy showed highly convoluted myonuclei. In immunofluorescent analysis, the TDP-43 binding partner TIA1 and TIA1 ligand G3BP showed increased expression. Matrin 3 analysed by western blotting showed no abnormalities compared to control (not shown).

Figure 1 Pedigree and muscle findings of the family. Pedigree of the family (A). Wasting of the first dorsal interossei and thenar muscle of patient II.2 is seen on the right side (B). T1-weighted axial MRI scans of the lower legs of patient II.2 show prominent fatty degenerative changes in the soleus and medial gastrocnemius selectively sparing the lateral gastrocnemius and without significant changes in the anterior compartment (C). H&E stain section shows fibres with rimmed-vacuolar changes. Myosin heavy chain (MyHC) double staining with normal fibre type distribution, variation in fibre size ranging from highly atrophic rounded fibres to hypertrophic fibres, and numerous mostly rounded atrophic fibres of both type 1 (brown) and type Ila (red). Myosin heavy chain neonatal (MHCn) and developmental (MHCd) antibody reactivity in highly atrophic fibres and in moderately atrophic fibres. In internalised nuclei the central part showed depletion of Matrin 3 immunostaining with strong irregular label in the nuclear membrane. Matrin 3 normal control muscle showed a uniform reactivity in all myonuclei. Electron micrograph (EM) of the abnormally convoluted nuclear membrane.
Exome sequencing revealed a known mutation in MATR3: c.254C>G, p. Ser85Cys (NM_199189.2). The mutation was Sanger sequenced and was present in all four of the affected siblings.

**DISCUSSION**

We report a new VCPDM family with the p.Ser85Cys mutation in MATR3 showing less bulbar involvement, but respiratory failure in some cases. MATR3 as a cause of ALS was initially reported by Johnson et al based on the identification of segregating mutations in several families and subsequently replicated in exome data derived from an independent cohort of patients diagnosed with familial ALS. The pattern of combined features of ALS and myopathy has been recognised with other ALS-causing genes such as CHCHD10, VCP, hnRNP A1 and hnRNP A2B1. An assessment for a potential motor neuron component in our family showed brisk reflexes raising the possibility of minor upper motor neuron pathology, but there were no lower motor neuron abnormalities to account for the muscle atrophy.

Late-onset distal weakness with vocal cord and pharyngeal involvement has been the clinical hallmark of VCPDM. However, bulbar symptoms can be absent in the beginning, as observed in our patients, and in a report of 16 German patients. Respiratory insufficiency was evident in half of our siblings. The phenotypic difference with this mutation is variable and the known hallmarks of the disease, dysphagia and dysphonias, can be subtle or absent. The distinct wasting of the first dorsal interossei and thenar muscles, with relative sparing of the hypothenar, was present in all four of the affected siblings.

The distinct wasting of the first dorsal interossei and thenar muscles, with relative sparing of the hypothenar, was present in all four of the affected siblings. The pattern of combined features of ALS and myopathy has been recognised with other ALS-causing genes such as CHCHD10, VCP, hnRNP A1 and hnRNP A2B1. An assessment for a potential motor neuron component in our family showed brisk reflexes raising the possibility of minor upper motor neuron pathology, but there were no lower motor neuron abnormalities to account for the muscle atrophy.

The cases reported here show that distinguishing between myogenic and neurogenic pathomechanisms requires careful assessment of clinical, electrophysiological, muscle morphological and muscle MRI techniques.

**Johanna Palmio,1 Anni Eviälä,2 Ayat Bashir,3 Fiona Norwood,4 Kati Vihola,4 Sanna Huovinen,5 Volker Straub,6 Peter Hackman,2 Michio Hirano,7 Kate Bushby,6 Bjarne Udd1,2,8**

1Department of Neurology, Neuromuscular Research Centre, Tampere University and University Hospital, Tampere, Finland
2Folkhälsoanstän of Genetics and the Department of Medical Genetics, Haartman Institute, University of Helsinki, Helsinki, Finland
3Newcastle University, Newcastle upon Tyne, UK
4Department of Neurology, King’s College Hospital, London, UK
5Department of Pathology, Fimlaboratories, Tampere University Hospital, Tampere, Finland
6Institute of Genetic Medicine, International Centre for Life, Newcastle University, Newcastle upon Tyne, UK
7Department of Neurology, Columbia University Medical Centre, New York, New York, USA
8Department of Neurology, Vasa Central Hospital, Vasa, Finland

**Correspondence to** Dr Johanna Palmio, Department of Neurology, Neuromuscular Research Centre, Tampere University and University Hospital, University of Tampere, Tampere 33014, Finland; johanna.palmio@uta.fi

**Acknowledgements** The Specialised Service for Rare Neuromuscular Diseases at Newcastle is funded by the NHS National Specialised services structure. The Newcastle Muscle team is part of the MRC Centre for Neuromuscular Diseases.

**Contributors** KB, BU were involved in the study conception and design. AE, AB, FN, KV, AV, SH, VS, MH, KB, BU were involved in the acquisition of data. JP, AE, FN, KV, AV, SH, VS, PH, MH, KB, BU were involved in the analysis and interpretation of data. JP, AB, VS, PH, MH, KB, BU were involved in the drafting and revision of the manuscript. BU obtained funding and involved in the study supervision.

**Funding** This work was supported by the Juelius Foundation as well as the Finnish Academy (BU).

**Competing interests** None declared.

**Patient consent** Obtained.

**Ethics approval** The study was carried out according to the ethical standards of the Helsinki declaration. All participants provided appropriate informed consent.

**Provenance and peer review** Not commissioned; externally peer reviewed.


Received 28 August 2014
Revised 11 March 2015
Accepted 14 April 2015

Published Online First 7 May 2015

J Neurol Neurosurg Psychiatry 2016;87:448–450.

doi:10.1136/jnnp-2014-309349

**REFERENCES**


Re-evaluation of the phenotype caused by the common MATR3 p.Ser85Cys mutation in a new family

Johanna Palmio, Anni Evilä, Ayat Bashir, Fiona Norwood, Kati Viitaniemi, Anna Vihola, Sanna Huovinen, Volker Straub, Peter Hackman, Michio Hirano, Kate Bushby and Bjarne Udd

J Neurol Neurosurg Psychiatry 2016 87: 448-450 originally published online May 7, 2015
doi: 10.1136/jnnp-2014-309349